These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 25358897)

  • 21. Bleeding assessment and bleeding severity in thrombocytopenic patients undergoing invasive procedures.
    van Baarle FEHP; van de Weerdt EK; Suurmond B; Müller MCA; Vlaar APJ; Biemond BJ
    Transfusion; 2020 Mar; 60(3):637-649. PubMed ID: 32003910
    [No Abstract]   [Full Text] [Related]  

  • 22. [The efficacy and safety of autologous cryopreserved platelet transfusion in management of thrombocytopenia after chemotherapy in hematological malignancy].
    Liu GQ; Ding HF; Lu XJ; Xu M; Xing J; Zhao X; Han F; Shang YH
    Zhonghua Nei Ke Za Zhi; 2012 Mar; 51(3):188-91. PubMed ID: 22781890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prophylactic platelet transfusions.
    Estcourt LJ; Stanworth SJ; Murphy MF
    Curr Opin Hematol; 2010 Sep; 17(5):411-7. PubMed ID: 20601869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The new paradigm for transfusion of platelets.
    Kaufman RM
    Clin Adv Hematol Oncol; 2015 May; 13(5):290-2. PubMed ID: 26352771
    [No Abstract]   [Full Text] [Related]  

  • 25. Supportive transfusion therapy in cancer patients with acquired defects of hemostasis.
    Federici AB; Intini D; Lattuada A; Vanelli C; Arrigoni L; Sacchi E; Russo U
    Thromb Res; 2014 May; 133 Suppl 2():S56-62. PubMed ID: 24862147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Platelet transfusion goals in oncology patients.
    Fasano RM; Josephson CD
    Hematology Am Soc Hematol Educ Program; 2015; 2015():462-70. PubMed ID: 26637759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The value of crossmatch tests and panel tests as a screening tool to predict the outcome of platelet transfusion in a non-selected haematological population of patients.
    Levin MD; van der Holt B; de Veld JC; Gratama JW; de Vries W; van't Veer MB
    Vox Sang; 2004 Nov; 87(4):291-8. PubMed ID: 15585026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comment on "Platelet transfusion: basic aspects".
    Arya SC; Agarwal N
    Swiss Med Wkly; 2014; 144():w13960. PubMed ID: 24706499
    [No Abstract]   [Full Text] [Related]  

  • 29. Dengue hemorrhagic fever in Trinidad and Tobago: a case for a conservative approach to platelet transfusion.
    Sharma A; Charles K; Chadee D; Teelucksingh S
    Am J Trop Med Hyg; 2012 Mar; 86(3):531-5. PubMed ID: 22403331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Individualized treatment for immune thrombocytopenia: predicting bleeding risk.
    Neunert CE
    Semin Hematol; 2013 Jan; 50 Suppl 1():S55-7. PubMed ID: 23664518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical aspects of treatment with platelet concentrates.
    Lanzer G
    Acta Anaesthesiol Scand Suppl; 1996; 109():141-3. PubMed ID: 8901986
    [No Abstract]   [Full Text] [Related]  

  • 32. New strategies for the optimal use of platelet transfusions.
    Blajchman MA; Slichter SJ; Heddle NM; Murphy MF
    Hematology Am Soc Hematol Educ Program; 2008; ():198-204. PubMed ID: 19074082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treating thrombocytopenia with pathogen-reduced platelets.
    Sandler SG
    Curr Hematol Rep; 2006 Mar; 5(1):53-4. PubMed ID: 16537046
    [No Abstract]   [Full Text] [Related]  

  • 34. [Platelet transfusions].
    Mandelli F
    Ric Clin Lab; 1976; 6 Suppl 1():73-6. PubMed ID: 802954
    [No Abstract]   [Full Text] [Related]  

  • 35. Thrombocytopenia and platelet transfusions in patients with cancer.
    Valent J; Schiffer CA
    Cancer Treat Res; 2011; 157():251-65. PubMed ID: 21052961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Compliance with prophylactic platelet transfusion trigger in haematological patients.
    Eikenboom JC; van Wordragen R; Brand A
    Transfus Med; 2005 Feb; 15(1):45-8. PubMed ID: 15713128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Managing of platelet transfusion refractoriness of haematological malignancies. Experience IPC-EFSAM].
    Dettori I; Ladaique P
    Transfus Clin Biol; 2014 Nov; 21(4-5):207-9. PubMed ID: 25267204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis.
    Stanworth SJ; Hudson CL; Estcourt LJ; Johnson RJ; Wood EM;
    Haematologica; 2015 Jun; 100(6):740-7. PubMed ID: 25795717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Issues in the management of cancer-related thrombocytopenia.
    Goodnough LT; DiPersio JF
    Oncology (Williston Park); 2002 Nov; 16(11):1558-67; discussion 1570, 1572-4. PubMed ID: 12469931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prophylactic platelet transfusions.
    Valeri CR; Ragno GM
    N Engl J Med; 2010 Jun; 362(22):2141; author reply 2141-2. PubMed ID: 20527061
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.